Incyte Corp. (INCY) Rose To A 3-Week High On Phase 3 Study Results

Incyte Corp. (INCY) announced Thursday morning that its Phase 3 study of baricitinib met its primary endpoint of improved ACR 20 response compared to placebo. Baricitinib is a treatment for moderate-to-severe rheumatoid arthritis.

from RTT - Before the Bell http://ift.tt/1MZikPZ
via IFTTT